Targeted Medical Pharma to Present at 2013 Southern California Investor Conference

Los Angeles, CA, August 6th, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies for the treatment of chronic disease, today announced that the company’s CEO and Chief Science Officer William Shell, M.D., will be presenting at the 2013 Southern California Investor Conference being held at the Island Hotel in Newport Beach, California on Thursday, August 8, 2013 at 8:30 a.m. PST.

Interested parties may listen to the presentation through a live audio webcast available at Listeners are encouraged to visit the website at least 15 minutes prior to the start of the scheduled presentation. A copy of the presentation also can be found by visiting the events and presentation section within the investor relations portion of Targeted Medical Pharma’s website or by clicking here.

According to a recent research report by Falls Church, VA-based Technology Catalysts International, the global medical foods market is estimated at approximately $12 billion and growing.  The report notes that consumer and scientific interest in the relationship between diet, health, and alternative medicines has created an increased demand for medical foods.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.


#   #   #